beta-alanine has been researched along with Blood Clot in 57 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to evaluate the feasibility of an oral direct thrombin inhibitor, dabigatran, as a periprocedural anticoagulant for use with ablation of atrial fibrillation (AF)." | 9.17 | A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. ( Hirayama, H; Inden, Y; Kamiya, H; Murohara, T; Nanasato, M; Nin, T; Sairaku, A; Tatematsu, Y; Yoshida, Y, 2013) |
| " We present a case in which a patient abruptly stopped taking dabigatran due to a small bowel obstruction and shortly thereafter suffered a myocardial infarction complicated by left ventricular thrombosis with fatal embolisation to the superior mesenteric artery." | 7.80 | Myocardial infarction complicated by left ventricular thrombus and fatal thromboembolism following abrupt cessation of dabigatran. ( Marciniak, ET; McCurdy, MT; Reed, RM; Weiler, B, 2014) |
| " After single intragastric administrations of HY023016, Dabigatran etexilate or tetramethylpyrazine, the anti-thrombotic activities were evaluated through rabbit jugular vein thrombosis model, rat inferior vena cava thrombosis model, ex vivo rabbit platelet aggregation assay, in vivo rabbit coagulation assay, and direct thrombin binding assay." | 7.79 | Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models. ( Gong, GQ; He, GW; Jiang, ML; Li, YZ; Wang, XH; Xu, YG; Yang, WH; Yang, XZ; Zhou, Y, 2013) |
| " This case report describes a patient with a St Jude aortic valve replacement who suffered valve thrombosis and an embolic stroke when anti-coagulated with the direct thrombin inhibitor dabigatran etexilate." | 7.78 | Thrombosis on a Mechanical Aortic Valve whilst Anti-coagulated With Dabigatran. ( Astell, H; Stewart, RA; White, HD; Young, L, 2012) |
| "Dabigatran is a novel direct thrombin inhibitor that has recently been approved for primary and secondary stroke prevention and prevention of systemic embolism in patients with atrial fibrillation." | 7.78 | Dabigatran for stroke prevention in atrial fibrillation. ( Diener, HC; Hohnloser, SH, 2012) |
| "Dabigatran is an oral anticoagulant that inhibits thrombin but not vitamin K." | 6.49 | Dabigatran: life-threatening bleeding. ( , 2013) |
| " Adjusted dosage of dabigatran to 110 mg/bid according to renal clearance in combination with 150 mg/day aspirin was started." | 5.39 | [Severe thrombosis of bioprosthesis mitral valve after dabigatran]. ( Akgüllü, C; Eryılmaz, U; Kurtoğlu, T, 2013) |
| "We undertook this prospective cohort study to determine the safety of 5 g of intravenous idarucizumab and its capacity to reverse the anticoagulant effects of dabigatran in patients who had serious bleeding (group A) or required an urgent procedure (group B)." | 5.20 | Idarucizumab for Dabigatran Reversal. ( Bernstein, RA; Dubiel, R; Eikelboom, J; Glund, S; Huisman, MV; Hylek, EM; Kam, CW; Kamphuisen, PW; Kreuzer, J; Levy, JH; Pollack, CV; Reilly, PA; Sellke, FW; Stangier, J; Steiner, T; Verhamme, P; Wang, B; Weitz, JI, 2015) |
| "We aimed to evaluate the feasibility of an oral direct thrombin inhibitor, dabigatran, as a periprocedural anticoagulant for use with ablation of atrial fibrillation (AF)." | 5.17 | A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. ( Hirayama, H; Inden, Y; Kamiya, H; Murohara, T; Nanasato, M; Nin, T; Sairaku, A; Tatematsu, Y; Yoshida, Y, 2013) |
| " Warfarin, the most commonly used vitamin K antagonist, has been shown to be highly effective in treating and preventing thrombosis." | 4.89 | Disadvantages of VKA and requirements for novel anticoagulants. ( Ansell, J; Shameem, R, 2013) |
| "We present data on possibility of anticoagulant therapy in conjunction with electrical cardioversion in patients with atrial fibrillation using novel anticoagulant - dabigatran - and a case of successful lysis of thrombus in the left ventricular cavity at the background of its administration." | 4.88 | [Anticoagulant therapy in connection with cardioversion in patients with atrial fibrillation]. ( Dovgalevskiĭ, IaP; Furman, NV; Kuvshinova, LE, 2012) |
| " We present a case in which a patient abruptly stopped taking dabigatran due to a small bowel obstruction and shortly thereafter suffered a myocardial infarction complicated by left ventricular thrombosis with fatal embolisation to the superior mesenteric artery." | 3.80 | Myocardial infarction complicated by left ventricular thrombus and fatal thromboembolism following abrupt cessation of dabigatran. ( Marciniak, ET; McCurdy, MT; Reed, RM; Weiler, B, 2014) |
| " After single intragastric administrations of HY023016, Dabigatran etexilate or tetramethylpyrazine, the anti-thrombotic activities were evaluated through rabbit jugular vein thrombosis model, rat inferior vena cava thrombosis model, ex vivo rabbit platelet aggregation assay, in vivo rabbit coagulation assay, and direct thrombin binding assay." | 3.79 | Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models. ( Gong, GQ; He, GW; Jiang, ML; Li, YZ; Wang, XH; Xu, YG; Yang, WH; Yang, XZ; Zhou, Y, 2013) |
| " This case report describes a patient with a St Jude aortic valve replacement who suffered valve thrombosis and an embolic stroke when anti-coagulated with the direct thrombin inhibitor dabigatran etexilate." | 3.78 | Thrombosis on a Mechanical Aortic Valve whilst Anti-coagulated With Dabigatran. ( Astell, H; Stewart, RA; White, HD; Young, L, 2012) |
| "Dabigatran is a novel direct thrombin inhibitor that has recently been approved for primary and secondary stroke prevention and prevention of systemic embolism in patients with atrial fibrillation." | 3.78 | Dabigatran for stroke prevention in atrial fibrillation. ( Diener, HC; Hohnloser, SH, 2012) |
| " Coagulation biomarkers in shed blood were assessed at 3 h after monotherapy with the medicines under study, at 3 h after triple therapy dosing and at steady state trough conditions." | 2.79 | Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects. ( Eichinger, S; Gouya, G; Kapiotis, S; Kyrle, PA; Litschauer, B; Mayer, P; Smerda, L; Weisshaar, S; Wolzt, M, 2014) |
| "Dabigatran is an oral anticoagulant that inhibits thrombin but not vitamin K." | 2.49 | Dabigatran: life-threatening bleeding. ( , 2013) |
| "Dabigatran is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity." | 2.47 | Pharmacological basis and clinical evidence of dabigatran therapy. ( Barez, A; Martínez, MP; Navarro-Dorado, J; Ramajo, M; Redondo, S; Tejerina, T, 2011) |
| " Orally administered dabigatran after discharge from hospital appears safe for venous thromboembolism prophylaxis after RALP." | 1.40 | Dabigatran for thromboprophylaxis after robotic assisted laparoscopic prostatectomy: retrospective analysis of safety profile and effect on blood coagulation. ( Joutsi-Korhonen, L; Lassila, R; Pétas, A; Rannikko, AS; Säily, VM; Taari, K, 2014) |
| "Dabigatran (220 mg/day) was prescribed as an outpatient treatment, and the disappearance of the LV thrombus was confirmed by UCG and CT 27 days after dabigatran initiation." | 1.40 | Resolution of a left ventricular thrombus by the thrombolytic action of dabigatran. ( Hayashida, K; Koga, Y; Matsuura, T; Mine, D; Nagamoto, Y; Okahara, A; Sadamatsu, K; Shiomi, T; Shirahama, T; Takegami, K; Yoshida, K, 2014) |
| "Fibrin-rich platelet thrombus formation was quantified by monitoring flow pressure changes." | 1.40 | Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model. ( Hosokawa, K; Koide, T; Maruyama, I; Miura, N; Ohnishi, T; Sameshima, H; Tanaka, KA, 2014) |
| " Adjusted dosage of dabigatran to 110 mg/bid according to renal clearance in combination with 150 mg/day aspirin was started." | 1.39 | [Severe thrombosis of bioprosthesis mitral valve after dabigatran]. ( Akgüllü, C; Eryılmaz, U; Kurtoğlu, T, 2013) |
| "Dabigatran (Pradaxa) is a member of the relatively new class of antithrombotic drugs known as direct thrombin inhibitors (DTIs)." | 1.38 | Dabigatran (Pradaxa). ( Comin, J; Kallmes, DF, 2012) |
| "Valve thrombus was observed in all study groups." | 1.38 | Dabigatran versus warfarin after mechanical mitral valve replacement in the swine model. ( Bianco, RW; Lahti, MT; Medina, EM; Schomburg, JL, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (3.51) | 29.6817 |
| 2010's | 55 (96.49) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, YZ | 1 |
| Gong, GQ | 1 |
| Yang, WH | 1 |
| Wang, XH | 1 |
| Jiang, ML | 1 |
| Zhou, Y | 1 |
| Yang, XZ | 1 |
| Xu, YG | 1 |
| He, GW | 1 |
| Lisman, T | 1 |
| Kamphuisen, PW | 2 |
| Northup, PG | 1 |
| Porte, RJ | 1 |
| Eby, C | 1 |
| Schmitt, AR | 1 |
| Zender, CA | 1 |
| Bordeaux, JS | 1 |
| Nagamoto, Y | 2 |
| Shiomi, T | 2 |
| Sadamatsu, K | 2 |
| Luis, SA | 1 |
| Poon, K | 1 |
| Luis, C | 1 |
| Shukla, A | 1 |
| Bett, N | 1 |
| Hamilton-Craig, C | 1 |
| Morita, S | 1 |
| Ajiro, Y | 1 |
| Uchida, Y | 1 |
| Iwade, K | 1 |
| Coulter, S | 1 |
| Campos, K | 1 |
| Baruch, L | 1 |
| Säily, VM | 1 |
| Pétas, A | 1 |
| Joutsi-Korhonen, L | 1 |
| Taari, K | 1 |
| Lassila, R | 1 |
| Rannikko, AS | 1 |
| Shameem, R | 1 |
| Ansell, J | 1 |
| Thomas, PA | 1 |
| Schaerf, NB | 1 |
| Rosenfeld, JV | 1 |
| Matsuura, T | 1 |
| Okahara, A | 1 |
| Takegami, K | 1 |
| Mine, D | 1 |
| Shirahama, T | 1 |
| Koga, Y | 1 |
| Yoshida, K | 1 |
| Hayashida, K | 1 |
| Akgüllü, C | 1 |
| Eryılmaz, U | 1 |
| Kurtoğlu, T | 1 |
| Chandler, WL | 1 |
| Fries, D | 1 |
| Giurea, A | 1 |
| Gütl, M | 1 |
| Halbmayer, WM | 1 |
| Kozek-Langenecker, S | 1 |
| Pachucki, A | 1 |
| Roithinger, F | 1 |
| Steinlechner, B | 1 |
| Thaler, H | 1 |
| Weltermann, A | 1 |
| Lee, CL | 1 |
| Wang, HH | 1 |
| Tsao, HM | 1 |
| Benzon, HT | 1 |
| Avram, MJ | 1 |
| Green, D | 1 |
| Bonow, RO | 1 |
| Hosokawa, K | 1 |
| Ohnishi, T | 1 |
| Sameshima, H | 1 |
| Miura, N | 1 |
| Koide, T | 1 |
| Maruyama, I | 1 |
| Tanaka, KA | 1 |
| Capodanno, D | 1 |
| Angiolillo, DJ | 1 |
| Yau, JW | 1 |
| Liao, P | 1 |
| Fredenburgh, JC | 1 |
| Roberts, RS | 1 |
| Weitz, JI | 3 |
| Konturek, P | 1 |
| Hess, T | 1 |
| Zeus, T | 1 |
| Nitschmann, S | 1 |
| Kelm, M | 1 |
| Weiler, B | 1 |
| Marciniak, ET | 1 |
| Reed, RM | 1 |
| McCurdy, MT | 1 |
| Frei, J | 1 |
| Carroll, VS | 1 |
| Weisshaar, S | 1 |
| Litschauer, B | 1 |
| Gouya, G | 1 |
| Mayer, P | 1 |
| Smerda, L | 1 |
| Kapiotis, S | 1 |
| Kyrle, PA | 1 |
| Eichinger, S | 1 |
| Wolzt, M | 1 |
| Ulrich, LR | 1 |
| Mergenthal, K | 1 |
| Petersen, JJ | 1 |
| Roehl, I | 1 |
| Rauck, S | 1 |
| Kemperdick, B | 1 |
| Schulz-Rothe, S | 1 |
| Berghold, A | 1 |
| Siebenhofer, A | 1 |
| Blann, AD | 1 |
| Zylla, MM | 1 |
| Pohlmeier, M | 1 |
| Hess, A | 1 |
| Mereles, D | 1 |
| Kieser, M | 1 |
| Bruckner, T | 1 |
| Scholz, E | 1 |
| Zitron, E | 1 |
| Schweizer, PA | 1 |
| Katus, HA | 1 |
| Thomas, D | 1 |
| Cantürk, E | 1 |
| Karaca, O | 1 |
| Omaygenç, O | 1 |
| Kızılırmak, F | 1 |
| Güler, E | 1 |
| Steiner, T | 2 |
| Pollack, CV | 1 |
| Reilly, PA | 1 |
| Eikelboom, J | 2 |
| Glund, S | 1 |
| Verhamme, P | 1 |
| Bernstein, RA | 1 |
| Dubiel, R | 1 |
| Huisman, MV | 1 |
| Hylek, EM | 1 |
| Kreuzer, J | 1 |
| Levy, JH | 1 |
| Sellke, FW | 1 |
| Stangier, J | 1 |
| Wang, B | 1 |
| Kam, CW | 1 |
| Miller, MW | 1 |
| Basra, S | 1 |
| Kulp, DW | 1 |
| Billings, PC | 1 |
| Choi, S | 1 |
| Beavers, MP | 1 |
| McCarty, OJ | 1 |
| Zou, Z | 1 |
| Kahn, ML | 1 |
| Bennett, JS | 1 |
| DeGrado, WF | 1 |
| Matute, MC | 1 |
| Guillán, M | 1 |
| García-Caldentey, J | 1 |
| Buisan, J | 1 |
| Aparicio, M | 1 |
| Masjuan, J | 1 |
| Alonso de Leciñana, M | 1 |
| Kazmi, RS | 1 |
| Lwaleed, BA | 1 |
| Stewart, RA | 1 |
| Astell, H | 1 |
| Young, L | 1 |
| White, HD | 1 |
| Van de Werf, F | 1 |
| Redondo, S | 1 |
| Martínez, MP | 1 |
| Ramajo, M | 1 |
| Navarro-Dorado, J | 1 |
| Barez, A | 1 |
| Tejerina, T | 1 |
| Pezzotti, W | 1 |
| Freuler, M | 1 |
| Comin, J | 1 |
| Kallmes, DF | 1 |
| Soff, GA | 1 |
| Duh, PD | 1 |
| Leuckx, PS | 1 |
| Warnez, PM | 1 |
| Deftereos, S | 1 |
| Anatoliotakis, N | 1 |
| Giannopoulos, G | 1 |
| Kaoukis, A | 1 |
| Mavri, M | 1 |
| Pyrgakis, V | 1 |
| Stefanadis, C | 1 |
| Schomburg, JL | 1 |
| Medina, EM | 1 |
| Lahti, MT | 1 |
| Bianco, RW | 1 |
| Vidal, A | 1 |
| Vanerio, G | 1 |
| Hohnloser, SH | 1 |
| Diener, HC | 1 |
| Thorne, KM | 1 |
| Dee, S | 1 |
| Jayathissa, S | 1 |
| Price, J | 1 |
| Hynes, M | 1 |
| Labinaz, M | 1 |
| Ruel, M | 1 |
| Boodhwani, M | 1 |
| Furman, NV | 1 |
| Kuvshinova, LE | 1 |
| Dovgalevskiĭ, IaP | 1 |
| Valle Bernad, R | 1 |
| Nin, T | 1 |
| Sairaku, A | 1 |
| Yoshida, Y | 1 |
| Kamiya, H | 1 |
| Tatematsu, Y | 1 |
| Nanasato, M | 1 |
| Inden, Y | 1 |
| Hirayama, H | 1 |
| Murohara, T | 1 |
| Ortel, TL | 1 |
| Gross, PL | 1 |
| Kis, Z | 1 |
| Földesi, C | 1 |
| Pál, M | 1 |
| Som, Z | 1 |
| Csillik, A | 1 |
| Abrahám, P | 1 |
| Temesvári, A | 1 |
| Fontos, G | 1 |
| Szatmári, A | 1 |
| Andréka, P | 1 |
| Kardos, A | 1 |
| Ogawa, T | 1 |
| Sugidachi, A | 1 |
| Naganuma, H | 1 |
| Asai, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Anticoagulant on Early Treatment of Post-STEMI Left Ventricular Thrombus: an Open, Prospective, Randomized and Multi-centers Trial.[NCT03764241] | Phase 3 | 280 participants (Anticipated) | Interventional | 2020-02-01 | Recruiting | ||
| Efficacy and Safety of Anticoagulant on Early Prevention of Post-STEMI Left Ventricular Thrombus: an Open, Prospective, Randomized and Multi-centers Trial.[NCT03786757] | Phase 3 | 200 participants (Anticipated) | Interventional | 2019-04-01 | Not yet recruiting | ||
| A Prospective, Randomized, Controlled, Analyst-blinded, Parallel Group Study to Investigate the Effect of Antithrombotic Triple Therapy With Ticagrelor and Acetylsalicylic Acid in Combination With Dabigatran or Rivaroxaban or Phenprocoumon on Markers of C[NCT01812200] | Phase 4 | 60 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| A Phase III Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of 5.0g Idarucizumab (BI 655075) in Patients Treated Wtih Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emerge[NCT02104947] | Phase 3 | 503 participants (Actual) | Interventional | 2014-05-06 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Cmin,1 (Minimum concentrations at any time point since the end of first vial of idarucizumab up to 4 hours after the completion of second vial) of unbound sum (free) dabigatran, provided that two vials given not more than 15 min apart in group A and B. (NCT02104947)
Timeframe: Since the end of first vial of idarucizumab up to 4 hours after the completion of second vial
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Idarucizumab (Group A & B) | 1.12 |
Occurrence of major/life-threatening/fatal bleeding (for group B only) intraoperatively and up to 24 hours post-surgery were classified according to major or life-threatening bleeding (ISTH [International Society for Thrombosis and Hemostasis] definition). 95% Confidence Interval (CI) is from Clopper-Pearson method. (NCT02104947)
Timeframe: within 24 hours of surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Idarucizumab (Group B) | 3.0 |
Time to cessation of bleeding (for Group A only) since first infusion up to 24 hours after the completion of second infusion; bleeding status was to be categorized before and at several time points after treatment. (NCT02104947)
Timeframe: from the first infusion up to 24 hours after the last infusion on Day 1
| Intervention | hours (Median) |
|---|---|
| ICH (Group A) | 10.73 |
| Non-ICH (Group A) | 2.49 |
Duration of reversal, defined as the time period a patient remained completely reversed based on dTT or ECT, up to 24 hours or re-starting the treatment of dabigatran. (NCT02104947)
Timeframe: from the first infusion up to 24 hours after the last infusion on Day 1
| Intervention | hours (Mean) | |
|---|---|---|
| ECT (# patients evaluable for reversal=276; 185) | dTT (# patients evaluable for reversal=244; 152) | |
| Idarucizumab (Group A) | 13.2 | 19.8 |
| Idarucizumab (Group B) | 12.8 | 18.8 |
"Maximum reversal of anticoagulant effect of dabigatran based on central laboratory determination of diluted thrombin time (dTT) or ecarin clotting time (ECT), at any time point from the end of the first infusion up to 4 hours after the last infusion.~Reversal is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% ULN (evaluable patients).~Reversal is calculated as 100* (pre-dose value minus post dose value)/(pre-dose value minus 100% x ULN); if calculated reversal is > 100, it was set to 100." (NCT02104947)
Timeframe: from the end of the first infusion up to 4 hours after the last infusion on Day 1
| Intervention | percentage (Median) | |
|---|---|---|
| dTT (# patients evaluable for reversal=244; 152) | ECT (# patients evaluable for reversal=276; 185) | |
| Idarucizumab (Group A) | 100.0 | 100.0 |
| Idarucizumab (Group B) | 100.0 | 100.0 |
"Reversal of anticoagulation as measured by diluted Thrombin Time (dTT) or Ecarin Clotting Time (ECT) after the first vial of idarucizumab and before the start of second vial.~Reversal is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% ULN (evaluable patients). Reversal is calculated as 100*(pre-dose value minus post dose value)/(pre-dose value minus 100% x ULN); if calculated reversal is > 100, it was set to 100." (NCT02104947)
Timeframe: after the first vial of idarucizumab and before the start of second vial on Day1
| Intervention | percentage (Median) | |
|---|---|---|
| dTT (# patients evaluable for reversal=240; 150) | ECT (# patients evaluable for reversal=271; 182) | |
| Idarucizumab (Group A) | 100.0 | 100.0 |
| Idarucizumab (Group B) | 100.0 | 100.0 |
"Reversal of anticoagulation as measured by Activated Partial Thromboplastin Time (aPTT) and Thrombin time (TT), at any time point since the end of first infusion up to 4 hours after the completion of the last infusion. Reversal is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% ULN (evaluable patients).~Reversal is calculated as 100* (pre-dose value minus post dose value)/(pre-dose value minus 100% x ULN); if calculated reversal is > 100, it was set to 100." (NCT02104947)
Timeframe: from the end of the first infusion up to 4 hours after the last infusion on Day 1
| Intervention | percentage (Median) | |
|---|---|---|
| aPTT (# patients evaluable for reversal=232; 141) | TT (# patients evaluable for reversal=278; 188) | |
| Idarucizumab (Group A) | 100.0 | 100.0 |
| Idarucizumab (Group B) | 100.0 | 100.0 |
20 reviews available for beta-alanine and Blood Clot
| Article | Year |
|---|---|
Dabigatran: life-threatening bleeding.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Interactions; | 2013 |
Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Disease Progression; Fibrinolytic | 2013 |
Novel anticoagulants and laboratory testing.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagula | 2013 |
Laboratory monitoring of anticoagulant medications: focus on novel oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Dr | 2013 |
Disadvantages of VKA and requirements for novel anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Dosage Calculat | 2013 |
New oral anticoagulants and regional anaesthesia.
Topics: Administration, Oral; Anesthesia, Conduction; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatr | 2013 |
Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzi | 2014 |
[Gastrointestinal bleeding under treatment with new oral anticoagulants].
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacemen | 2014 |
Oral anticoagulants: the move beyond warfarin.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Human | 2014 |
Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relati | 2014 |
New anticoagulants: how to deal with treatment failure and bleeding complications.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Rivaroxab | 2011 |
Pharmacological basis and clinical evidence of dabigatran therapy.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Kidney Failur | 2011 |
Using anticoagulants to steer clear of clots.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; H | 2012 |
A new generation of oral direct anticoagulants.
Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimi | 2012 |
[Pharmacological sheet. Dabigatran, oral administration (Pradaxa)].
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Fibrinolytic Agent | 2012 |
Novel direct factor IIa and Xa inhibitors: mechanisms of action and preclinical studies.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Evaluation, Preclinical; Fac | 2012 |
Dabigatran and left atrial appendage thrombus.
Topics: Antithrombins; Atrial Appendage; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart Diseases; H | 2012 |
[Anticoagulant therapy in connection with cardioversion in patients with atrial fibrillation].
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Blood Coa | 2012 |
Perioperative management of patients on chronic antithrombotic therapy.
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic A | 2012 |
New oral anticoagulants: which one should my patient use?
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Chemistry, Pharmaceutical; Clini | 2012 |
4 trials available for beta-alanine and Blood Clot
| Article | Year |
|---|---|
[Re-allign (randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran ftexilate in patients after heart valve replacement)].
Topics: Administration, Oral; Adolescent; Adult; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatr | 2014 |
Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects.
Topics: Adenosine; Administration, Oral; Adult; Anticoagulants; Antithrombin III; Aspirin; Austria; Benzimid | 2014 |
Idarucizumab for Dabigatran Reversal.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Anticoagulants; Benzimidazoles; beta-Ala | 2015 |
A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; | 2013 |
33 other studies available for beta-alanine and Blood Clot
| Article | Year |
|---|---|
Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models.
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Disease Models, Animal; Mice; Prod | 2013 |
A new oral anticoagulant in the setting of dermatologic surgery.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Derma | 2013 |
Thrombolytic action of dabigatran in patients with acute pre-existing atrial thrombus.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Echocardiography, Transe | 2013 |
Massive left atrial thrombus in a patient with rheumatic mitral stenosis and atrial fibrillation while anticoagulated with dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Substitution; Ec | 2013 |
Dabigatran for left atrial thrombus.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart Atria; Heart Diseases; | 2013 |
Thrombosis on a mechanical mitral valve anticoagulated with dabigatran.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Prosthesis; | 2014 |
Dabigatran and mechanical valves: less effective and more risky than warfarin.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Prosthesis; Heart Valve Prosth | 2013 |
Dabigatran for thromboprophylaxis after robotic assisted laparoscopic prostatectomy: retrospective analysis of safety profile and effect on blood coagulation.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Humans; Laparoscopy; Mal | 2014 |
Dabigatran - neurosurgical anathema?
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Male; Risk Assess | 2013 |
Resolution of a left ventricular thrombus by the thrombolytic action of dabigatran.
Topics: Aged; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Heart Diseases; Heart Ventricle | 2014 |
Resolution of a left ventricular thrombus by the thrombolytic action of dabigatran.
Topics: Aged; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Heart Diseases; Heart Ventricle | 2014 |
Resolution of a left ventricular thrombus by the thrombolytic action of dabigatran.
Topics: Aged; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Heart Diseases; Heart Ventricle | 2014 |
Resolution of a left ventricular thrombus by the thrombolytic action of dabigatran.
Topics: Aged; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Heart Diseases; Heart Ventricle | 2014 |
[Severe thrombosis of bioprosthesis mitral valve after dabigatran].
Topics: Adult; Antithrombins; Benzimidazoles; beta-Alanine; Bioprosthesis; Dabigatran; Female; Heart Valve P | 2013 |
Anticoagulation without monitoring.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Hemorrhage; Heparin; Huma | 2013 |
Management of dabigatran-induced bleeding: expert statement.
Topics: Administration, Oral; Antithrombins; Austria; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; | 2013 |
The antithrombotic effect of dabigatran.
Topics: Aged; Antithrombins; Atrial Appendage; Benzimidazoles; beta-Alanine; Dabigatran; Diagnosis, Differen | 2014 |
Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model.
Topics: Adenosine Triphosphate; Adult; Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; | 2014 |
Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits.
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Catheter Obstruction; Catheters; Dabigatran; D | 2014 |
Myocardial infarction complicated by left ventricular thrombus and fatal thromboembolism following abrupt cessation of dabigatran.
Topics: Aged, 80 and over; Angiography; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Fatal Outco | 2014 |
Anticoagulant treatment in German family practices - screening results from a cluster randomized controlled trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; | 2014 |
Prevalence of intracardiac thrombi under phenprocoumon, direct oral anticoagulants (dabigatran and rivaroxaban), and bridging therapy in patients with atrial fibrillation and flutter.
Topics: Aged; Anticoagulants; Arrhythmias, Cardiac; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran | 2015 |
Case images: warfarin-induced skin necrosis: a 'novel' solution to an old problem.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Diagnosis, Differential; Hu | 2014 |
[Antidote to dabigatran].
Topics: Antibodies, Monoclonal, Humanized; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Ris | 2015 |
Small-molecule inhibitors of integrin alpha2beta1 that prevent pathological thrombus formation via an allosteric mechanism.
Topics: Allosteric Regulation; Animals; beta-Alanine; Fibrinolytic Agents; Humans; Integrin alpha2beta1; Mic | 2009 |
Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran.
Topics: Aged; Antithrombins; Aphasia; Benzimidazoles; beta-Alanine; Carotid Artery Diseases; Dabigatran; Fem | 2011 |
Thrombosis on a Mechanical Aortic Valve whilst Anti-coagulated With Dabigatran.
Topics: Aortic Valve; Aortic Valve Stenosis; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Dr | 2012 |
Dabigatran for patients with a mechanical valve.
Topics: Benzimidazoles; beta-Alanine; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Humans; I | 2012 |
Dabigatran (Pradaxa).
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Hemorrha | 2012 |
Dabigatran versus warfarin after mechanical mitral valve replacement in the swine model.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Evaluation, Preclinical; Fem | 2012 |
Dabigatran for stroke prevention in atrial fibrillation.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicin | 2012 |
Thrombotic events after discontinuing dabigatran: rebound or resumption?
Topics: Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Middle Aged; Re | 2012 |
Mechanical valve thrombosis with dabigatran.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Diagnosis, Differential; Echocardiography, | 2012 |
[Introduction].
Topics: Acenocoumarol; Anticoagulants; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans | 2012 |
[Percutaneous left atrial appendage closure after resolution of left atrial appendage thrombi with dabigatran].
Topics: Anticoagulants; Antithrombins; Atherectomy; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; b | 2013 |
Antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs.
Topics: Adenosine Diphosphate; Administration, Oral; Alanine; Animals; Arteriovenous Shunt, Surgical; Aspiri | 2000 |